The Claim
The combined use of fecal pks gene detection and tumor mutational signature analysis identifies colibactin-associated activity in 87% of unexplained polyposis patients with SBS88/ID18-positive lesions, compared to 25% of those without such lesions, indicating that the combination of these two biomarkers improves detection of colibactin exposure relative to either biomarker alone.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with unexplained polyps and specific DNA damage patterns, detecting a bacterial gene in stool along with a unique tumor mutation pattern identifies colibactin exposure in 87% of cases, compared to 25% when only one method is used.
See the scientific wording
The combination of fecal pks gene detection and tumor mutational signature analysis identified colibactin-associated activity in 87% of unexplained polyposis patients with SBS88/ID18-positive lesions, compared to 25% of those without, suggesting that these two biomarkers together better identify colibactin exposure than either alone.
What the research says
1 studyScientists found that when they checked both poop for harmful bacteria genes and tumors for specific DNA damage patterns, they could spot colibactin’s fingerprint much better than using just one method. This helps explain why some people get lots of polyps.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.